<unk>  is a rifamycin antibacterial that is FDA approved for the treatment of travelers’ diarrhea (TD) caused by noninvasive strains of Escherichia coli and reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ≥ 18 years of age.   Common adverse reactions include flatulence, headache, abdominal pain, rectal tenesmus, defecation urgency, nausea, peripheral edema, dizziness, fatigue, and ascites.
Rifaximin
Chenodeoxycholic acid
Ethulose
Lactulose
Piretanide
Sucralfate
Rifapentine
Bisacodyl